- Stockholm-based BOOST Pharma, a clinical-stage biopharmaceutical firm concentrating on innovative cell therapies for rare pediatric skeletal diseases, has announced the successful acquisition of an additional €3.1 million in funding. This investment comes from Sound Bioventures, which has joined the existing investor syndicate to bolster BOOST Pharma’s mission.
- The newly raised funds are aimed at advancing BOOST Pharma’s clinical programs, particularly those targeting genetic bone diseases in children. These conditions often lead to severe health complications and impact the quality of life, making effective treatments critical. The company is committed to developing novel therapies that can significantly improve patient outcomes.
- In a statement, BOOST Pharma emphasized the importance of this financial support in accelerating their research and development efforts. The leadership expressed gratitude towards Sound Bioventures for their confidence in the company’s vision and the potential impact of its therapies on the lives of affected children.
Source: Swedish Tech News
Leave feedback about this
You must be logged in to post a comment.